Montelukast For Mild And Moderate AECOPD In Patients With IL-8,Blood Gas Analysis And Pulmonary Function

Objective: chronic obstructive pulmonary disease is a preventable, treatable disease, characterized by limited airflow, is not fully reversible airflow limited, and development was carried out with the lungs of cigarette smoke and other harmful gases or harmful particles of the abnormal inflammatory response. the pathogenesis of COPD is complexity .airway inflammation in COPD is play a critical role in the pathogenesis . It thinks a variety of inflammatory cells (neutrophils, CD8+Tlymphocytes) and inflammatory mediators (leukotrienes, IL-8.etc) involved in the occurrence of airway inflammation Montelukast is a leukotriene receptor antagonist, there are clinical studies have shown the stability of montelukast in patients with a view of the clinical symptoms of COPD and lung function have a certain degree of improvement. This study will further observation of montelukast in patients with acute exacerbation of COPD in the IL-8, lung function and blood gas analysis for the clinical treatment of COPD to provide a basis.Methods: In December 2007 to January 2009 The First Affiliated Hospital of Shanxi Medical University, cadres and respiratory medicine wards of the hospital diagnosed patients with COPD included in the study. All patients were selected in line with:①All patients have cough, sputum, shortness of breath, and (or) add to breathing, increased sputum volume, purulent or purulent mucus, fever may be accompanied by symptoms in short-term.②All patients in bronchodilator inhalation drug FEV1/FVC <70%, while FEV1≥80% is expected to value or 50%≤FEV1 <80% expected value. Patients were randomly assigned to treatment group and control group, 20 cases of the control group, only conventional treatment, including antibiotic therapy, oxygen therapy, expectorant and bronchodilator. Conventional therapy plus montelukast 20 cases specially designed for the treatment group, treatment time 14 days before treatment and treatment at the end of recording and analysis of patients with the following information:1. The general situation: age, sex, smoking index2. Indicators of pulmonary ventilation: FEV1% pred, FEV1/FVC 3. Indicators of arterial blood gas: PaO2,PaCO2, PH, HCO3-4. Sputum and blood levels of IL-8Statistical methods:Using SPSS 13.0 statistical analysis software package.values are reported as mean±standard deviation, Data do not comply with normal distribution,use rank sum test .significance was accepted at (P<0.05). Results: 1. Treatment before and after the treatment group of indicators of pulmonary ventilation (FEV1%pred, FEV1/FVC) differences were statistical significance (P<0.01) Treatment before and after the control group of indicators of pulmonary ventilation (FEV1% pred, FEV1/FVC) differences were statistical significance (P<0.05). However, the treatment group compared with the control group differences were Statistical significance2. Treatment before and after the treatment group of indicators of arterial blood gas (PaO2)differences were statistical significance (P<0.01), Treatment before and after the control group of indicators of arterial blood gas (PaO2)differences were statistical significance (P<0.05) . However, the treatment group compared with the control group differences were Statistical significance (P<0.05).The remaining indicators(PaCO2, PH, HCO3- ) differences were not statistical significance (P>0.05).3. Treatment before and after the treatment group of IL-8 in sputum and blood differences were Statistical significance (P<0.01), Treatment before and after the control group of IL-8 in sputum and blood differences were Statistical significance (P<0.05). However, the treatment group compared with the control group differences were Statistical significance (P<0.05).Conclusion: A leukotriene receptor antagonist-montelukast in mild and moderate AECOPD in patients with short-term improvements in lung function, improve blood pressure, lower blood and sputum IL-8 level, to reduce airway inflammation Therefore montelukast could be considered as anti-inflammatory drugs in mild and moderate acute AECOPD of patients use.